Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Thrombopoietin protects hematopoietic stem cells from retrotransposon-mediated damage by promoting an antiviral response.

Barbieri D, Elvira-Matelot E, Pelinski Y, Genève L, de Laval B, Yogarajah G, Pecquet C, Constantinescu SN, Porteu F.

J Exp Med. 2018 May 7;215(5):1463-1480. doi: 10.1084/jem.20170997. Epub 2018 Apr 3.

2.

Age-Associated Decrease of the Histone Methyltransferase SUV39H1 in HSC Perturbs Heterochromatin and B Lymphoid Differentiation.

Djeghloul D, Kuranda K, Kuzniak I, Barbieri D, Naguibneva I, Choisy C, Bories JC, Dosquet C, Pla M, Vanneaux V, Socié G, Porteu F, Garrick D, Goodhardt M.

Stem Cell Reports. 2016 Jun 14;6(6):970-984. doi: 10.1016/j.stemcr.2016.05.007.

3.

IER3 supports KRASG12D-dependent pancreatic cancer development by sustaining ERK1/2 phosphorylation.

Garcia MN, Grasso D, Lopez-Millan MB, Hamidi T, Loncle C, Tomasini R, Lomberk G, Porteu F, Urrutia R, Iovanna JL.

J Clin Invest. 2014 Nov;124(11):4709-22. doi: 10.1172/JCI76037. Epub 2014 Sep 24.

4.

Interleukin-18 produced by bone marrow-derived stromal cells supports T-cell acute leukaemia progression.

Uzan B, Poglio S, Gerby B, Wu CL, Gross J, Armstrong F, Calvo J, Cahu X, Deswarte C, Dumont F, Passaro D, Besnard-Guérin C, Leblanc T, Baruchel A, Landman-Parker J, Ballerini P, Baud V, Ghysdael J, Baleydier F, Porteu F, Pflumio F.

EMBO Mol Med. 2014 Jun;6(6):821-34. doi: 10.1002/emmm.201303286. Epub 2014 Apr 6.

5.

SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia.

Pasmant E, Gilbert-Dussardier B, Petit A, de Laval B, Luscan A, Gruber A, Lapillonne H, Deswarte C, Goussard P, Laurendeau I, Uzan B, Pflumio F, Brizard F, Vabres P, Naguibvena I, Fasola S, Millot F, Porteu F, Vidaud D, Landman-Parker J, Ballerini P.

Oncogene. 2015 Jan 29;34(5):631-8. doi: 10.1038/onc.2013.587. Epub 2014 Jan 27.

PMID:
24469042
6.

Thrombopoietin promotes NHEJ DNA repair in hematopoietic stem cells through specific activation of Erk and NF-κB pathways and their target, IEX-1.

de Laval B, Pawlikowska P, Barbieri D, Besnard-Guerin C, Cico A, Kumar R, Gaudry M, Baud V, Porteu F.

Blood. 2014 Jan 23;123(4):509-19. doi: 10.1182/blood-2013-07-515874. Epub 2013 Nov 1.

7.

Thrombopoietin-increased DNA-PK-dependent DNA repair limits hematopoietic stem and progenitor cell mutagenesis in response to DNA damage.

de Laval B, Pawlikowska P, Petit-Cocault L, Bilhou-Nabera C, Aubin-Houzelstein G, Souyri M, Pouzoulet F, Gaudry M, Porteu F.

Cell Stem Cell. 2013 Jan 3;12(1):37-48. doi: 10.1016/j.stem.2012.10.012. Epub 2012 Dec 13.

8.

ERK1 regulates the hematopoietic stem cell niches.

Saulnier N, Guihard S, Holy X, Decembre E, Jurdic P, Clay D, Feuillet V, Pagès G, Pouysségur J, Porteu F, Gaudry M.

PLoS One. 2012;7(1):e30788. doi: 10.1371/journal.pone.0030788. Epub 2012 Jan 30.

9.

p-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes.

Frisan E, Pawlikowska P, Pierre-Eugène C, Viallon V, Gibault L, Park S, Mayeux P, Dreyfus F, Porteu F, Fontenay M.

Haematologica. 2010 Nov;95(11):1964-8. doi: 10.3324/haematol.2010.024349. Epub 2010 Sep 7.

10.

ATM-dependent expression of IEX-1 controls nuclear accumulation of Mcl-1 and the DNA damage response.

Pawlikowska P, Leray I, de Laval B, Guihard S, Kumar R, Rosselli F, Porteu F.

Cell Death Differ. 2010 Nov;17(11):1739-50. doi: 10.1038/cdd.2010.56. Epub 2010 May 14.

11.

The MAPK ERK1 is a negative regulator of the adult steady-state splenic erythropoiesis.

Guihard S, Clay D, Cocault L, Saulnier N, Opolon P, Souyri M, Pagès G, Pouysségur J, Porteu F, Gaudry M.

Blood. 2010 May 6;115(18):3686-94. doi: 10.1182/blood-2009-09-242487. Epub 2010 Mar 11.

PMID:
20223923
12.

Gfi-1B promoter remains associated with active chromatin marks throughout erythroid differentiation of human primary progenitor cells.

Laurent B, Randrianarison-Huetz V, Kadri Z, Roméo PH, Porteu F, Duménil D.

Stem Cells. 2009 Sep;27(9):2153-62. doi: 10.1002/stem.151.

13.

Inhibition of B56-containing protein phosphatase 2As by the early response gene IEX-1 leads to control of Akt activity.

Rocher G, Letourneux C, Lenormand P, Porteu F.

J Biol Chem. 2007 Feb 23;282(8):5468-77. Epub 2007 Jan 2.

14.

B56-containing PP2A dephosphorylate ERK and their activity is controlled by the early gene IEX-1 and ERK.

Letourneux C, Rocher G, Porteu F.

EMBO J. 2006 Feb 22;25(4):727-38. Epub 2006 Feb 2.

15.

Thrombopoietin regulates IEX-1 gene expression through ERK-induced AML1 phosphorylation.

Hamelin V, Letourneux C, Romeo PH, Porteu F, Gaudry M.

Blood. 2006 Apr 15;107(8):3106-13. Epub 2005 Dec 20.

PMID:
16368886
16.

Reply to 'hRap1B-retro: a novel human processed Rap1B gene blurs the picture?' by Zemojtel et al.

Gyan E, Porteu F, Fontenay M.

Leukemia. 2006 Jan;20(1):146-147. No abstract available.

PMID:
16307014
17.

Mutation in RAP1 is a rare event in myelodysplastic syndromes.

Gyan E, Frew M, Bowen D, Beldjord C, Preudhomme C, Lacombe C, Mayeux P, Dreyfus F, Porteu F, Fontenay M.

Leukemia. 2005 Sep;19(9):1678-80. No abstract available.

PMID:
16118622
18.

The cancer chemopreventive agent resveratrol induces tensin, a cell-matrix adhesion protein with signaling and antitumor activities.

Rodrigue CM, Porteu F, Navarro N, Bruyneel E, Bracke M, Romeo PH, Gespach C, Garel MC.

Oncogene. 2005 May 5;24(20):3274-84.

PMID:
15735708
19.

Development of T-cell lymphomas in Emu-IEX-1 mice.

Zhang Y, Finegold MJ, Porteu F, Kanteti P, Wu MX.

Oncogene. 2003 Oct 9;22(44):6845-51.

PMID:
14534530
20.

Activation of the mitogen-activated protein kinases Erk1/2 by erythropoietin receptor via a G(i )protein beta gamma-subunit-initiated pathway.

Guillard C, Chrétien S, Pelus AS, Porteu F, Muller O, Mayeux P, Duprez V.

J Biol Chem. 2003 Mar 28;278(13):11050-6. Epub 2003 Jan 21.

21.

IEX-1: a new ERK substrate involved in both ERK survival activity and ERK activation.

Garcia J, Ye Y, Arranz V, Letourneux C, Pezeron G, Porteu F.

EMBO J. 2002 Oct 1;21(19):5151-63.

22.

Requirement for mitogen-activated protein kinase activation in the response of embryonic stem cell-derived hematopoietic cells to thrombopoietin in vitro.

Filippi MD, Porteu F, Le Pesteur F, Schiavon V, Millot GA, Vainchenker W, de Sauvage FJ, Dubart Kupperschmitt A, Sainteny F.

Blood. 2002 Feb 15;99(4):1174-82.

PMID:
11830463
23.

Cloning and characterization of a family of proteins associated with Mpl.

Meunier C, Bordereaux D, Porteu F, Gisselbrecht S, Chrétien S, Courtois G.

J Biol Chem. 2002 Mar 15;277(11):9139-47. Epub 2002 Jan 9.

24.

Role of Gab proteins in phosphatidylinositol 3-kinase activation by thrombopoietin (Tpo).

Bouscary D, Lecoq-Lafon C, Chrétien S, Zompi S, Fichelson S, Muller O, Porteu F, Dusanter-Fourt I, Gisselbrecht S, Mayeux P, Lacombe C.

Oncogene. 2001 Apr 26;20(18):2197-204.

25.
26.

Embryonic stem cell differentiation to hematopoietic cells: A model to study the function of various regions of the intracytoplasmic domain of cytokine receptors in vitro.

Filippi MD, Porteu F, Le Pesteur F, Rameau P, Nogueira MM, Debili N, Vainchenker W, de Sauvage FJ, Kupperschmitt AD, Sainteny F.

Exp Hematol. 2000 Dec;28(12):1363-72.

PMID:
11146158
27.

A new feature of Mpl receptor: ligand-induced transforming activity in FRE rat fibroblasts.

Challier C, Cocault L, Flon M, Pauchard M, Porteu F, Gisselbrecht S, Souyri M.

Oncogene. 2000 Apr 13;19(16):2033-42.

28.

Megakaryocyte growth and development factor-induced proliferation and differentiation are regulated by the mitogen-activated protein kinase pathway in primitive cord blood hematopoietic progenitors.

Fichelson S, Freyssinier JM, Picard F, Fontenay-Roupie M, Guesnu M, Cherai M, Gisselbrecht S, Porteu F.

Blood. 1999 Sep 1;94(5):1601-13.

PMID:
10477685
29.

Thrombopoietin-induced expression of the glycoprotein IIb gene involves the transcription factor PU.1/Spi-1 in UT7-Mpl cells.

Doubeikovski A, Uzan G, Doubeikovski Z, Prandini MH, Porteu F, Gisselbrecht S, Dusanter-Fourt I.

J Biol Chem. 1997 Sep 26;272(39):24300-7.

30.

Control of thrombopoietin-induced megakaryocytic differentiation by the mitogen-activated protein kinase pathway.

Rouyez MC, Boucheron C, Gisselbrecht S, Dusanter-Fourt I, Porteu F.

Mol Cell Biol. 1997 Sep;17(9):4991-5000.

31.

Functional regions of the mouse thrombopoietin receptor cytoplasmic domain: evidence for a critical region which is involved in differentiation and can be complemented by erythropoietin.

Porteu F, Rouyez MC, Cocault L, Bénit L, Charon M, Picard F, Gisselbrecht S, Souyri M, Dusanter-Fourt I.

Mol Cell Biol. 1996 May;16(5):2473-82.

32.

Tyrosine phosphorylation of the erythropoietin receptor: role for differentiation and mitogenic signal transduction.

Gobert S, Porteu F, Pallu S, Muller O, Sabbah M, Dusanter-Fourt I, Courtois G, Lacombe C, Gisselbrecht S, Mayeux P.

Blood. 1995 Jul 15;86(2):598-606.

PMID:
7541671
33.

Neutrophil expression of tumour necrosis factor receptors (TNF-R) and of activation markers (CD11b, CD43, CD63) in rheumatoid arthritis.

Lopez S, Halbwachs-Mecarelli L, Ravaud P, Bessou G, Dougados M, Porteu F.

Clin Exp Immunol. 1995 Jul;101(1):25-32.

34.
35.

Human neutrophils release their major membrane sialoprotein, leukosialin (CD43), during cell activation.

Rieu P, Porteu F, Bessou G, Lesavre P, Halbwachs-Mecarelli L.

Eur J Immunol. 1992 Nov;22(11):3021-6.

PMID:
1358626
36.

Regulation of tumor necrosis factor receptors on phagocytes.

Ding AH, Porteu F.

Proc Soc Exp Biol Med. 1992 Sep;200(4):458-65. Review. No abstract available.

PMID:
1354872
37.
39.

Complement alternative pathway activation and control on membranes of human lymphoid B cell lines.

Caudwell V, Porteu F, Calender A, Pangburn MK, Halbwachs-Mecarelli L.

Eur J Immunol. 1990 Dec;20(12):2643-50.

PMID:
1702720
40.
41.

Shared actions of endotoxin and taxol on TNF receptors and TNF release.

Ding AH, Porteu F, Sanchez E, Nathan CF.

Science. 1990 Apr 20;248(4953):370-2.

PMID:
1970196
42.
43.

C3b receptor (CR1) on phagocytic cells from SLE patients: analysis of the defect and familial study.

Mir A, Porteu F, Levy M, Lesavre P, Halbwachs-Mecarelli L.

Clin Exp Immunol. 1988 Sep;73(3):461-6.

45.

Modulation of neutrophil expression of C3b receptors (CR1) by soluble monomeric human C3b.

Porteu F, Mir A, Halbwachs-Mecarelli L.

Eur J Immunol. 1987 May;17(5):629-35.

PMID:
2953614
46.

Defective complement receptors (CR1 and CR3) on erythrocytes and leukocytes of factor I (C3b-inactivator) deficient patients.

Porteu F, Fischer A, Descamps-Latscha B, Halbwachs-Mecarelli L.

Clin Exp Immunol. 1986 Nov;66(2):463-71.

Supplemental Content

Loading ...
Support Center